Decision Science Can Inform Clinical Trade-Offs Regarding Cardiotoxic Cancer Treatments

Arielle S. Gillman, PhD, MPH1, Jacqueline B. Vo, PhD, RN, MPH2, Anju Nohria, MD, MSc3, Rebecca A. Ferrer, PhD4

1. Cancer Prevention Fellowship Program, Basic Biobehavioral and Psychological Sciences Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
2. Cancer Prevention Fellowship Program, Radiation Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, MD
3. Director, Cardio-oncology program, Dana Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA
4. Basic Biobehavioral and Psychological Sciences Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD

Correspondence concerning this paper should be addressed to: Arielle S. Gillman, Ph.D., MPH 9609 Medical Center Drive, #3E-216, Rockville, MD 20850. Email: arielle.gillman@nih.gov Phone: (240) 276-5892
Abstract

Cancer treatment-related cardiotoxicity (i.e., heart failure, coronary artery disease, vascular diseases, arrhythmia) is a growing cancer survivorship concern within oncology practice; heart disease is the leading cause of non-cancer death in cancer survivors and surpasses cancer as the leading cause of death for some cancers with higher survival rates. The issue of cardiotoxicity introduces a critical tradeoff that must be acknowledged and reconciled in clinical oncology practice: treating cancer aggressively and effectively in the present versus preventing future cardiotoxicity. Although many cancers must be treated as aggressively as possible, for others, multiple treatment options are available. Yet even when effective and less-cardiotoxic treatments are available, they are not always chosen. Wariness to choose equally effective but less cardiotoxic treatment options may result in part from providers’ and patients’ reliance on ‘cognitive heuristics’, or mental shortcuts that people (including, research shows, medical professionals) use to simplify complex judgments. These heuristics include delay discounting, availability and affect heuristics, and default bias. In the current commentary, we describe relevant research that illuminates how use of heuristics leads to biased medical decision making and translate how this research may apply when the tradeoff between aggressive cancer treatment and preventing future cardiotoxicity is considered. We discuss the implications of these biases in oncology practice, offer potential solutions to reduce bias, and call for future research in this area.
Cancer treatment-related cardiotoxicity (or cardiovascular toxicity, i.e., heart failure, coronary artery disease, vascular diseases, arrhythmia) is a growing cancer survivorship concern within oncology practice. Though advances in cancer treatment have contributed to improved cancer-specific survival rates over the past several decades\textsuperscript{1-3}, these improvements often involve a cost: “adverse effects” of cancer treatment—including cardiovascular side effects or cardiotoxicity from some treatments. Cardiotoxicity can affect patients “acutely” (during treatment) or “late” (years after completion of treatment), causing substantial declines in quality of life and increases in cardiovascular morbidity and mortality. Treatments with well-documented risk of cardiotoxicity include anthracyclines (e.g., doxorubicin, epirubicin), radiation to the chest wall, and trastuzumab\textsuperscript{4}. Using these cardiotoxic treatments in combination can increase risk considerably. Notably, heart disease is the leading cause of non-cancer death in cancer survivors, and has begun to approach or surpass cancer as the leading cause of death for some cancers with higher survival rates\textsuperscript{5}.

Accumulating evidence shows that anthracycline-induced cardiotoxicity affects nearly 6\textendash18\%\textsuperscript{6} of patients and can be seen up to 40 years after treatment completion\textsuperscript{7}. Heart disease risk increases with greater cumulative lifetime dose of anthracyclines\textsuperscript{8}. Further, the risk of heart disease increases when anthracyclines are used concomitantly with trastuzumab or radiation\textsuperscript{4}. Heart disease resulting from radiation therapy is often seen five years after treatment completion and increases linearly with mean radiation doses to the heart\textsuperscript{9}. While cardiotoxicity may occur acutely, it is important to note the impact of late effects that arise long after treatment has ended.

Risk of cardiotoxicity introduces a critical tradeoff that must be acknowledged and reconciled in oncology practice: treating cancer aggressively and effectively in the present versus preventing cardiotoxicity in the future. Although many cancers must be treated as aggressively as
possible, often including the use of potentially cardiotoxic treatments, for others, multiple treatment options can be effective.

For example, early stage, HER2-negative breast cancer patients may receive either 1) doxorubicin/epirubicin and cyclophosphamide [AC]; or 2) docetaxel and cyclophosphamide [TC]. Recent trials have demonstrated only marginal improvement\textsuperscript{10} or no difference\textsuperscript{11} in breast cancer survival with AC versus TC, which is important since AC carries substantial increased risk of cardiotoxicity compared to TC. As another example, for early stage HER2-positive, lymph node-positive breast cancers, adjuvant treatment may consist of 1) doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, and pertuzumab (AC-THP) or 2) docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP). Recent studies demonstrated no difference in breast cancer survival rates by inclusion of anthracyclines\textsuperscript{12–14}, but AC-THP has a substantially higher risk of cardiotoxicity due to the combination of anthracyclines with trastuzumab\textsuperscript{15,16}. Since both regimens contain trastuzumab, a targeted therapy aimed at inhibiting the HER2 receptor, a less cardiotoxic option would be selecting TCHP, removing the additional risk of cardiotoxicity due to anthracyclines. Of course, breast cancer is a heterogenous disease and avoiding cardiotoxic treatments in certain cases is not possible (e.g., triple negative breast cancer\textsuperscript{17}). However, when the opportunity is available, selecting a less or non-cardiotoxic option would minimize cardiotoxicity risk later.

Additionally, treatment of favorable prognosis, early-stage Hodgkin lymphoma typically involves either: 1) doxorubicin, bleomycin, vinblastine, dacarbazine [ABVD] chemotherapy followed by chest radiation; or 2) ABVD alone. While radiation after ABVD has demonstrated benefits for disease-specific survival, these benefits may be offset by delayed cardiotoxic effects\textsuperscript{18} (up to 20 years after radiation\textsuperscript{19}), risk for which is greater when radiation is combined...
with anthracycline chemotherapy\textsuperscript{19–21}. Here, omitting chest radiation is an option to minimize the risk of delayed cardiotoxicity.

Factors at multiple levels of the healthcare system can affect cancer treatment choices, including treatment availability, cost, insurance coverage, and clinical guidelines. Yet, critically for the purposes of the current commentary, there is also a “human factor” in the decision making process; typically, the oncologist presents the patient with multiple treatment options, risks and benefits of each are discussed, and a decision is reached over which treatment to ultimately proceed with\textsuperscript{22–24}. Within this decision-making process, oncologists and patients alike may be wary of forgoing use of aggressive yet cardiotoxic cancer treatments, even when other evidence-based treatments are available, as evidenced by the continued use of cardiotoxic therapies in cases such as the examples described above. We propose that this wariness may result in part from reliance on ‘cognitive heuristics’, or mental shortcuts that people use to simplify complex judgments\textsuperscript{25}. Certain heuristics are known to affect provider and patient medical decision making\textsuperscript{26} and are particularly relevant to the features of this particular tradeoff. These include: 1) delay discounting; 2) availability and affect heuristics; and 3) default bias. Reliance on heuristics is often adaptive, in that they allow for quick, efficient decision making and often lead to advantageous outcomes; however, there is a wide literature base demonstrating that reliance on heuristics can, in some circumstances, lead to biased decision making, including among physicians\textsuperscript{27–30}. Moreover, in some contexts, experts may be even more susceptible to decision-making biases than novice decision makers\textsuperscript{31}. Translating established, empirical research on these biases to help understand tradeoff decisions involving cardiotoxic cancer treatments can help guide more informed decisions in this context. Importantly, even decisions influenced by complex, multilevel factors can be improved when efforts are made to reduce
reliance on cognitive heuristics\textsuperscript{32–34}. Below, we review the decision science literature to identify principles that should be taken into account when informing optimal decision-making in this context.

**Delay discounting bias**

Individuals tend to favor immediate over delayed outcomes\textsuperscript{35} when given such an ‘intertemporal choice’—a bias termed ‘delay discounting’. Deciding whether to prescribe or use cancer treatments known to have late-onset cardiotoxic effects is a classic example of intertemporal choice (i.e., choosing the “immediate” outcome of aggressively treating cancer now to reduce a health risk in the present versus the “delayed” outcome of preventing cardiotoxicity to reduce a health risk in the future). Conceptualizing the reduction of a health risk as an “outcome” that can be traded off over time may be somewhat counterintuitive when compared to something tangible, such as money, because individuals cannot guarantee good health in either the present or future—they can only influence the probability of being in good health. That said, individuals still demonstrate present-time biases for health tradeoffs as they do with tangible monetary rewards\textsuperscript{36}.

The tendency to overvalue present outcomes is exacerbated when the time delay between present and future outcomes is larger and when present outcomes are seen as equivalent or greater than future outcomes, but can occur even when future gains severely outweigh present gains\textsuperscript{35}. Moreover, some individuals are more susceptible to this bias than others. These individual differences in preferences for immediate versus delayed outcomes may predict cancer treatment preferences of patients\textsuperscript{37} and clinical decisions by providers\textsuperscript{38,39}. Additionally, people have difficulty imagining how they will feel in the future in response to an affectively-laden
event they are not experiencing in the present (deemed the ‘hot-cold empathy gap’). This may exacerbate delay discounting in this context, as patients and providers are unlikely to be able to fully imagine how they would feel in the future if today’s cancer treatment were to create cardiotoxic late effects.

While it is an understandable human desire to fix an immediate problem now and delay consideration of the consequences of that decision until necessary, given the clear evidence regarding the prevalence and seriousness of cardiotoxic late effects of certain cancer treatments, oncology providers should be aware of delay discounting bias when making treatment decisions.

**Availability and affect heuristics**

Despite the fact that heart disease is more common than cancer, about half of Americans believe that cancer is more common than heart disease, and nearly 80% believe their own risk of cancer is higher than or equal to their risk of heart disease. Individuals also tend to report believing cancer is a more common cause of death than heart disease. This is important because risk perceptions are a key predictor in models of medical decision making, and if individuals have inaccurate perceptions about the risk of heart disease compared to cancer, they are unlikely to take steps to mitigate that risk. Several potential explanations may contribute to inaccurate risk perceptions for heart disease versus cancer. One is the ‘availability heuristic’, through which people judge outcomes as more likely if they are able to retrieve greater instances of that outcome from memory. Media coverage of celebrity cancer deaths and exposure to awareness campaigns may contribute to incorrect public perceptions that cancer risk is higher than heart disease risk. Also underlying these imbalanced risk perceptions is the ‘affect heuristic’; people use their emotions to inform their judgments of personal susceptibility, and cancer is considered
a uniquely frightening disease\textsuperscript{46,47}.

Although one might expect that medical professionals would be less susceptible to biased risk perceptions, research suggests otherwise\textsuperscript{48}. Moreover, medical oncologists who are exposed daily to the reality of a cancer diagnosis think of heart disease risk comparatively less often, which could exacerbate availability biases related to cancer as well as reduce affective risk perceptions for heart disease. These biased comparative risk perceptions could cause imbalances in the way providers weight the potential of cardiotoxic late effects with their perception of the need to eradicate cancer as aggressively as possible. The fact that oncology providers consider delayed consequences pertaining to cancer (e.g., prescribing adjuvant hormonal therapy to women with early-stage breast cancer to reduce the risk of cancer recurrence) but often do not extend the same logic to cardiotoxicity suggests that there is indeed some degree of imbalance in the way that cancer vs. heart disease risks influence decision making.

Similarly, biased comparative risk perceptions among patients may render them less receptive to less aggressive (but perhaps similarly effective and less cardiotoxic) therapies, and bias how they communicate such preferences with their providers. In line with this assertion, a recent study found that healthy participants were more willing to use a hypothetical medication that reduced cancer risk and increased heart disease risk than if that medication reduced heart disease risk and increased cancer risk by the same amount\textsuperscript{49}. While this decision was hypothetical, it nonetheless sheds light on the very real potential that biased risk perceptions could be consequential for patient decisions.

Availability bias can affect medical decision-making in consequential ways outside of risk perceptions. For example, when asked to provide primary treatment recommendations for a prostate cancer case scenario, radiation oncologists and urologists were more likely to
recommend primary treatments that favored their specialty, and to report believing treatment in line with their specialty would lead to better quality of life for the patient\textsuperscript{29}. These findings are likely due in part to availability bias, and it is reasonable to think that specialty bias could also apply to clinical oncologists without overlapping expertise in cardiology. In fact, a recent survey of cardiologists and oncologists found that cardiologists were much more likely than oncologists (55.8\% vs. 12.5\%) to believe it was important to monitor cancer patients for cardiotoxicity even in the absence of signs or symptoms, suggesting that specialty bias likely does play a role in clinical decision making in this context\textsuperscript{50}.

Thus, biases resulting from over-reliance on availability or affect heuristics may implicitly or explicitly affect tradeoffs guiding treatment decisions in oncology.

**Default bias**

When individuals make choices that involve a default option, they are much more likely to choose to maintain the status quo\textsuperscript{51}, including among physicians and for consequential medical decisions (termed ‘default bias’ or ‘status quo bias’)\textsuperscript{52}. Individuals likely gravitate toward default options because defaults are viewed as normatively preferred and because deviating from the default involves effort and increased personal responsibility\textsuperscript{53}. Cardiotoxic treatments can be conceptualized as the default treatment option for several cancers; anthracyclines have been a critical element of many chemotherapy regimens since the 1980s\textsuperscript{54} and radiation therapy for longer.

Thus, wariness towards less cardiotoxic treatment alternatives may reflect providers’ resistance to change\textsuperscript{54} and preferences to support existing default or status quo options. This desire is also likely to be transferred to the patient; patients are much more likely to choose the
option presented to them by their provider as the default\textsuperscript{55}. Moreover, default bias becomes stronger in medical decisions when more alternatives are added to set of choices\textsuperscript{52}. As such, default bias may be increasingly relevant as new alternatives to cardiotoxic regimens become available\textsuperscript{27}. Thus, when effective alternatives to treatments with risk of cardiotoxicity exist, it may be prudent for those options to be widely endorsed by the oncology community as the default (a shift in default treatment options may already be occurring in some cases, evidenced by declining use of anthracyclines over time for certain cancers\textsuperscript{56}).

**Practical Implications**

**Clinical guidelines for preventing cardiotoxicity: increasing awareness and adherence**

The oncology community has begun to reckon with the tradeoffs involved in treatment decision making when cardiotoxicity risk is involved\textsuperscript{57}, yet, there is limited data to support decision making at this point of care. Considering how best to make these tradeoffs is of growing importance in clinical oncology practice. For example, increasing awareness of treatment-related cardiotoxicity has contributed to the development of clinical guidelines, which can serve two purposes: 1) increasing awareness of cardiotoxicity among oncologists and patients to facilitate treatment decision-making regarding potential cardiotoxic risk, or 2) in the case where the more cardiotoxic treatment option is necessary, facilitating the care and management of patients who receive cardiotoxic treatment.

In 2017, the American Society of Clinical Oncology (ASCO) released clinical practice guidelines as one of the first organizations to address how to care and manage cardiovascular disease specifically related to cancer treatment. Recommendations include identifying patients at high risk by treatment type: 1) high dose anthracyclines, 2) high dose radiation, 3) combination
of lower dose anthracycline with lower dose radiation, 4) trastuzumab with anthracycline, 5) anthracycline or trastuzumab with preexisting cardiovascular risk factors. Critically, ASCO recommends avoiding or minimizing use of cardiotoxic treatments if alternatives exist that do not affect cancer-specific outcomes. Another recommended strategy to minimize risk of cardiotoxicity includes limiting lifetime cumulative dose of anthracyclines (doxorubicin 400 mg/m², epirubicin 600 mg/m²), due to increasing cardiotoxicity risk with higher doses.

In situations where cardiotoxic cancer treatment outweighs alternatives and must be used, it is important to manage the patient’s cardiovascular disease risk. At diagnosis, it is crucial to assess and manage pre-existing cardiovascular risk factors including smoking, hypertension, dyslipidemia, obesity, and diabetes. When administering chest radiation, clinicians should use the lowest effective radiation dose and use precise therapy to limit exposure to the heart (e.g., deep breath hold to shift the heart out of the radiation field and intensity-modulated radiation). Prior to, during, and after treatment, oncologists should collaborate with cardiologists or cardio-oncologists to ensure appropriate monitoring of cardiac function in high-risk patients. Importantly, some of the biases we discuss above in relation to the treatment decision-making process (e.g., inaccurate risk perceptions for heart disease) may also partially explain poor adherence to guidelines for monitoring cardiac function in patients treated with cardiotoxic treatments.

Lastly, two other frameworks are available to increase understanding and knowledge of cardiotoxicity risk. The National Comprehensive Cancer Network (NCCN) has a framework for assessing risk of cardiotoxicity in patients who have received anthracycline therapy. Incorporating the framework into electronic health records to pre-populate risk or management strategies could be an option to minimize long-term effects. Another strategy is the
development of the ABCDE steps to prevent heart disease in breast cancer patients. This tool could increase awareness for both oncology providers and patients to understand risk factors and cardiovascular symptoms through an acronym: awareness of risks for heart disease, aspirin, blood pressure, cholesterol, cigarette/tobacco cessation, diet and weight management, dose of chemotherapy, diabetes management, exercise, and echocardiogram. Providers also should assess patients’ understanding and perception of cardiovascular disease severity and potential side effects (i.e., shortness of breath, fatigue, swelling)—keeping in mind that patients’ existing perceptions are likely affected by the biased processes we discuss in this commentary, including inaccurate risk perceptions for heart disease versus cancer that stem from affect and availability heuristics.

Despite recent development of guidelines and evidence that early detection and intervention can mitigate cardiac damage from cancer treatment, in a recent study, only 65% of oncologists reported that they refer to clinical guidelines for decision making, and only 12% of oncologists believe that cardiotoxicity should be monitored in asymptomatic patients. Therefore, ensuring awareness of clinical guidelines and utilizing multidisciplinary collaboration is important to provide holistic care of the cancer patient. Moreover, the growing field of cardio-oncology, which is made up of experts and providers who are well versed in the intersection of oncology and cardiology, is well positioned to address these issues. Such providers are less likely to demonstrate biases in favor of treating cancer at the cost of cardiac health and may be able to provide more objective guidance for high-risk patients. Unfortunately, currently, cardio-oncology clinics are concentrated in large academic centers but are not prevalent in community cancer centers, which is likely to exacerbate disparities until these clinics can reach a wider group of patient populations.
Long-term survival of cancer survivors highlights the need for care beyond oncology. Primary care providers are uniquely positioned to provide long-term continuity of care\textsuperscript{62}. Primary care providers can monitor cardiovascular risk factors, obtain cardiovascular monitoring as indicated based on treatment and facilitate patients’ uptake of healthy lifestyle recommendations to reduce modifiable cardiovascular risk factors\textsuperscript{63}. Yet, primary care providers must be made aware of and acknowledge the potential cardiotoxic effects of cancer treatment. In 2016, Runowicz and colleagues published breast cancer survivorship guidelines on behalf of the American Cancer Society and ASCO to provide recommendations for primary care clinicians. Successful multidisciplinary collaboration between oncologists, cardiologists/cardio-oncologists, and primary care providers can help mitigate late and long-term cardiovascular effects of cancer treatment. 

**Opportunities for decision science to inform clinical practice**

As we have highlighted in this commentary, decision-making biases are consequential in medical decision making and may implicitly or explicitly contribute to providers’ and patients’ resistance to limiting use of certain cancer treatments despite evidence of their cardiotoxic effects. Although there are situations in which such treatments are necessary, when effective non-cardiotoxic alternative treatments are available, yet not chosen, we suggest that clinical oncology practitioners consider how these decision-making biases play a role in such decisions and attempt to counter any unnecessary bias. Importantly, people may be more likely to use heuristics with outgroup (e.g., those outside one’s racial, ethnic, gender, or nationality group) compared to ingroup members\textsuperscript{64}, so these biases may exacerbate health inequities in cardiovascular outcomes among cancer survivors\textsuperscript{65}. 
Given how these biases might lead to challenges in cardiotoxicity-related decision making, what can be done to guide patients and providers toward better choices? An early step is educating the medical oncology community about biases, which we have attempted to initiate in this commentary and which has been shown to improve doctors’ decision-making in certain contexts. Importantly, research suggests that physician motivations are likely to (implicitly or explicitly) drive shared decision making for cancer treatments, more so than patient motivations and preferences. Further, patients often rely on providers to qualitatively interpret numerical risk estimates for them; that is, if the risk of a side effect for a medication is 10%, patients will typically turn to their provider’s interpretation when deciding whether a numerically-represented risk estimate is “high” or “low.” Thus, it is the role of the provider to transparently discuss risks and benefits of treatment options when relevant, help patients make meaningful interpretations of risk estimates, ensure their comprehension, and allow patients to take time to absorb complex information before coming to a decision. Taking care to clearly explain (and not downplay) risks of cardiotoxicity to patients may be critical.

However, education about biases only improves decision making to a degree. Unfortunately, there is currently a lack of high-quality interventions that attempt to formally reduce cognitive biases among providers. Nevertheless, decision science research suggests some additional potential solutions, including the use of cognitive strategies to reduce bias. Interventions that help individuals better predict how they will react to a future decision can reduce the hot-cold empathy gap that is involved in delay discounting errors. Delay discounting may be mitigated in other ways, for example, through helping individuals orient their attention to the future. Findings like this might be translated to clinical practice through prompting patients to consider how the treatment decision they make will affect them both in the short term (e.g., 1-
5 years) and in the long term (e.g., 10 or 20 years from now), and similarly, through prompting clinicians to focus more attention onto long-term consequences of treatment decisions for their patients in addition to shorter-term consequences. Mindfulness-based interventions, which have wide-ranging benefits for cancer survivors outside of the treatment decision making context, may also help to reduce delay discounting bias, as reported in a systematic review.

With regard to reduction of bias caused by the availability and affect heuristics, one solution is through the utilization of evidence-based methods of risk communication to characterize the risk of cancer versus cardiotoxicity risks of different treatment options. For example, decision aids are commonly used in the field to support shared decision making in cancer care. However, we caution that the majority of studied decision aids have been developed without specific grounding theories in decision science, which may explain their mixed effects on health-related outcomes. Moving forward, knowledge about biases should be incorporated when developing shared treatment decision-making tools, and empirically-supported strategies to combat these biases should be utilized. For example, risks surrounding cancer treatments can be better understood if they are communicated using evidence-based methods, such as through the use of pictographs.

Finally, the power of defaults can be harnessed positively by the medical oncology community by ensuring that the most cardiotoxic treatments are not perceived as the default option if there is a reasonable, less cardiotoxic alternative, and instead shifting the default toward treatment options that are less cardiotoxic or non-cardiotoxic. Such a shift is less about individual-level communication on part of the provider and more of a shift at the systemic level, which is also a critical approach to the problem. Implementing the clinical practice guidelines surrounding cardiotoxicity that we discussed above is one way to begin a broad shift in oncology
toward the prevention of cardiotoxicity.

**Summary and Conclusion**

We have outlined how several well-researched judgment and decision-making biases may impact clinical decisions related to cancer treatments with cardiotoxic effects, based on research in other domains, medical or otherwise, which we expect should generalize to this context. However, no current empirical research that we know of has examined the extent to which these or other biases may affect decision-making in this specific context, nor whether interventions to reduce cognitive biases may improve outcomes in this domain. This topic is a critical avenue for future research. Additionally, these processes likely generalize to decisions about other cancer treatments that involve temporal tradeoffs. For example, treatment decision making involves weighing immediate effectiveness of treatments with other long-term risks and toxicities, including second cancers or cognitive impairments. Similarly, cancer treatments that may have reproductive effects involve a similar time-related tradeoff, where individuals may have to weigh the benefits of beginning cancer treatment immediately versus delaying cancer treatment slightly to take measures to preserve long-term fertility in adolescent and young adult cancer survivors. In sum, decision science can illuminate how clinical tradeoffs in oncology are navigated, and ultimately help survivors live healthy and long lives after cancer.

**Funding**

Not applicable.

**Notes**
Role of the funder: Not applicable.

Disclosures: Anju Nohria discloses financial relationships: Amgen, Inc. (research support) and Takeda Oncology (DSMB – consultant). Arielle Gillman, Jacqueline Vo, and Rebecca Ferrer have no disclosures to report.

Author Contributions: Conceptualization: ASG, JBV, RAF; Writing – original draft: ASG, JBV; Writing – review and editing: ASG, JBV, RAF, AN; Supervision: RAF, AN.

Disclaimer: The opinions expressed by the authors are their own and this material should not be interpreted as representing the official viewpoint of the U.S. Department of Health and Human Services, the National Institutes of Health or the National Cancer Institute.

Acknowledgements: Anju Nohria is supported by the Catherine Geoff Fitch fund and the Gelb Master Clinician fund.

Data Availability

Not applicable.

References

1. McGowan J V., Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. *Cardiovasc Drugs Ther*. 2017;31(1):63-75. doi:10.1007/s10557-016-6711-0

2. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. *J Natl Cancer Inst*. 2008;100(1):14-20. doi:10.1093/jnci/djm252

3. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of
modern chemotherapy for patients with node-positive breast cancer. *J Am Med Assoc.* 2006;295(14):1658-1667. doi:10.1001/jama.295.14.1658

4. Mehta LS, Watson KE, Barac A, et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. *Circulation.* 2018;137(8):e30-e66. doi:10.1161/CIR.0000000000000556

5. Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. *Eur Heart J.* 2019;40(48):3889-3897.

6. Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. *Am J Cardiol.* 2013;112(12):1980-1984. doi:10.1016/j.amjcard.2013.08.026

7. Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. *JAMA - J Am Med Assoc.* 2010;304(2):172-179. doi:10.1001/jama.2010.923

8. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. *Cancer.* 2003;97(11):2869-2879. doi:10.1002/cncr.11407

9. Darby SC, Ewertz M, McGale P, et al. Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer. *N Engl J Med.* 2013;368(11):987-998. doi:10.1056/NEJMoa1209825

10. Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). In: *Journal of Clinical Oncology.* Vol 35. American Society of Clinical Oncology; 2017:2647-2655. doi:10.1200/JCO.2016.71.4147
11. Nitz U, Gluz O, Clemens M, et al. West German study PlanB trial: Adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. In: *Journal of Clinical Oncology*. Vol 37. American Society of Clinical Oncology; 2019:799-808. doi:10.1200/JCO.18.00028

12. Burstein HJ, Piccart-Gebhart MJ, Perez EA, et al. Choosing the best trastuzumab-based adjuvant chemotherapy regimen: Should we abandon anthracyclines? *J Clin Oncol*. 2012;30(18):2179-2182. doi:10.1200/JCO.2012.42.0695

13. Reeder-Hayes KE, Meyer AM, Hinton SP, Meng K, Carey LA, Dusetzina SB. Comparative toxicity and effectiveness of trastuzumab-based chemotherapy regimens in older women with early-stage breast cancer. *J Clin Oncol*. 2017;35(29):3298-3305. doi:10.1200/JCO.2016.71.4345

14. Spring L, Niemierko A, Haddad S, et al. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. *Breast Cancer Res Treat*. 2018;172(3):733-740. doi:10.1007/s10549-018-4959-8

15. Bowles EJA, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. *J Natl Cancer Inst*. 2012;104(17):1293-1305.

16. Thavendiranathan P, Abdel-Qadir H, Fischer HD, et al. Breast cancer therapy–related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. *J Clin Oncol*. 2016;34(19):2239-2246.

17. Chen X, Ye G, Zhang C, Li X, Shen K. Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with
docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: Updated follow-up data from NATT study. *Chinese J Cancer Res.* 2016;28(6):561-569. doi:10.21147/j.issn.1000-9604.2016.06.02

18. de Vries S, Schaapveld M, Janus CPM, et al. Long-term cause-specific mortality in hodgkin lymphoma patients. *JNCI J Natl Cancer Inst.* December 2020. doi:10.1093/jnci/djaa194

19. Aleman BMP, Van Den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. *Blood.* 2007;109(5):1878-1886. doi:10.1182/blood-2006-07-034405

20. Van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. *Blood.* 2017;129(16):2257-2265. doi:10.1182/blood-2016-09-740332

21. Van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. *J Clin Oncol.* 2016;34(3):235-243. doi:10.1200/JCO.2015.63.4444

22. Panje CM, Glatzer M, Sirén C, Plasswilm L, Putora PM. Treatment Options in Oncology. *JCO Clin Cancer Informatics.* 2018;(2):1-10. doi:10.1200/cci.18.00017

23. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. *J Gen Intern Med.* 2012;27(10):1361-1367.

24. Barry MJ, Edgman-Levitan S. Shared Decision Making — The Pinnacle of Patient-Centered Care. *N Engl J Med.* 2012;366(9):780-781. doi:10.1056/nejmp1109283

25. Gilovich T, Griffin D, Kahneman D. *Heuristics and Biases: The Psychology of Intuitive
26. Braverman JA, Blumenthal-Barby JS. Assessment of the sunk-cost effect in clinical decision-making. *Soc Sci Med.* 2012;75(1):186-192. doi:10.1016/j.socscimed.2012.03.006

27. Bornstein BH, Emler AC. Rationality in medical decision making: a review of the literature on doctors’ decision-making biases. *J Eval Clin Pract.* 2001;7(2):97-107. doi:10.1046/j.1365-2753.2001.00284.x

28. Brewer NT, Chapman GB, Schwartz JA, Bergus GR. The Influence of Irrelevant Anchors on the Judgments and Choices of Doctors and Patients. *Med Decis Mak.* 2007;27(2):203-211. doi:10.1177/0272989X06298595

29. Kim SP, Gross CP, Nguyen PY, et al. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. *Prostate Cancer Prostatic Dis.* 2014;17(2):163-169. doi:10.1038/pcan.2014.3

30. Perneger TV, Agoritsas T. Doctors and patients’ susceptibility to framing bias: A randomized trial. *J Gen Intern Med.* 2011;26(12):1411-1417. doi:10.1007/s11606-011-1810-x

31. Reyna VF, Chick CF, Corbin JC, Hsia AN. Developmental Reversals in Risky Decision Making. *Psychol Sci.* 2014;25(1):76-84. doi:10.1177/0956797613497022

32. Soll JB, Milkman KL, Payne JW. A user’s guide to debiasing. 2014.

33. Morewedge CK, Yoon H, Scopelliti I, Symborski CW, Korris JH, Kassam KS. Debiasing Decisions. *Policy Insights from Behav Brain Sci.* 2015;2(1):129-140. doi:10.1177/2372732215600886

34. Kostopoulou O, Porat T, Corrigan D, Mahmoud S, Delaney BC. Diagnostic accuracy of GPs when using an early intervention decision support system: A high-fidelity simulation.
Br J Gen Pract. 2017;67(656):e201-e208. doi:10.3399/bjgp16X688417

35. Chapman GB, Elstein AS. Valuing the Future. Med Decis Mak. 1995;15(4):373-386. doi:10.1177/0272989X9501500408

36. Pol M van der, Irvine A. Time Preferences for Health. October 2018. doi:10.1093/ACREFORE/9780190625979.013.87

37. López-Pérez B, Barnes A, Frosch DL, Hanoch Y. Predicting prostate cancer treatment choices: The role of numeracy, time discounting, and risk attitudes. J Health Psychol. 2017;22(6):788-797. doi:10.1177/1359105315615931

38. Höjgärd S, Enemark U, Lyttkens CH, Lindgren A, Troëng T, Weibull H. Discounting and clinical decision making: Physicians, patients, the general public, and the management of asymptomatic abdominal aortic aneurysms. Health Econ. 2002;11(4):355-370. doi:10.1002/hec.674

39. Ortendahl M, Fries JF. Discounting and risk characteristics in clinical decision-making. Med Sci Monit. 2006;12(3):RA41-RA45.

40. Loewenstein G. Hot-cold empathy gaps and medical decision making. Heal Psychol. 2005;24(4 SUPPL.). doi:10.1037/0278-6133.24.4.S49

41. Scheideler JK, Taber JM, Ferrer RA, Grenen EG, Klein WMP. Heart disease versus cancer: understanding perceptions of population prevalence and personal risk. J Behav Med. 2017;40(5):839-845. doi:10.1007/s10865-017-9860-0

42. Prendergast HM, Bunney EB, Roberson T, Davis T. Knowledge of heart disease among women in an urban emergency setting. J Natl Med Assoc. 2004;96(8):1027-1031. doi:10.1016/j.annemergmed.2004.07.342

43. Ferrer RA, Klein WMP, Persoskie A, Avishai-Yitshak A, Sheeran P. The Tripartite Model
of Risk Perception (TRIRISK): Distinguishing Deliberative, Affective, and Experiential Components of Perceived Risk. *Ann Behav Med.* 2016;50(5):653-663. doi:10.1007/s12160-016-9790-z

44. Tversky A, Kahneman D. Availability: A heuristic for judging frequency and probability. *Cogn Psychol.* 1973;5(2):207-232. doi:10.1016/0010-0285(73)90033-9

45. Klein WMP, Ferrer RA, Graff KA, Kaufman AR, Han PKJ. Perceived ambiguity, fatalism, and believing cancer is more prevalent than heart disease. *Am J Prev Med.* 2014;46(4):e45-e47. doi:10.1016/j.amepre.2014.01.003

46. Ferrer RA, Green PA, Barrett LF. Affective Science Perspectives on Cancer Control: Strategically Crafting a Mutually Beneficial Research Agenda. *Perspect Psychol Sci.* 2015. doi:10.1177/1745691615576755

47. Finucane ML, Alhakami A, Slovic P, Johnson SM. The affect heuristic in judgments of risks and benefits. *J Behav Decis Mak.* 2000;13(1):1-17. doi:10.1002/(SICI)1099-0771(200001/03)13:1<1::AID-BDM333>3.0.CO;2-S

48. Adam MB, Reyna VF. Coherence and correspondence criteria for rationality: experts’ estimation of risks of sexually transmitted infections. *J Behav Decis Mak.* 2005;18(3):169-186. doi:10.1002/bdm.493

49. Ellis EM, Klein WMP, Orehek E, Ferrer RA. Effects of Emotion on Medical Decisions Involving Tradeoffs. *Med Decis Mak.* 2018;38(8):1027-1039. doi:10.1177/0272989X18806493

50. Peng J, Rushton M, Johnson C, et al. An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatments. *Cardio-Oncology.* 2019;5(1):1-8. doi:10.1186/s40959-019-0049-2
51. Jachimowicz JM, Duncan S, Weber EU, Johnson EJ. When and why defaults influence decisions: a meta-analysis of default effects. *Behav Public Policy*. January 2019:1-28. doi:10.1017/bpp.2018.43

52. Redelmeier DA, Shafir E. Medical Decision Making in Situations That Offer Multiple Alternatives. *JAMA J Am Med Assoc*. 1995;273(4):302-305. doi:10.1001/jama.1995.03520280048038

53. Ojerholm E, Halpern SD, Bekelman JE. Default Options: Opportunities to Improve Quality and Value in Oncology. *J Clin Oncol*. 2016;34(16):1844-1847. doi:10.1200/JCO.2015.64.8741

54. Crozier JA, Swaike A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines. *World J Clin Oncol*. 2014;5(3):529-538. doi:10.5306/wjco.v5.i3.529

55. Ozdemir S, Finkelstein EA. Cognitive Bias: The Downside of Shared Decision Making. *JCO Clin Cancer Informatics*. 2018;(2):1-10. doi:10.1200/cci.18.00011

56. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. *J Clin Oncol*. 2012;30(18):2232-2239. doi:10.1200/JCO.2011.40.1273

57. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines: Survivorship)*.; 2019.

58. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. *J Clin Oncol*. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400

59. Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and
Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. *JACC Cardiovasc Imaging*. 2018;11(8):1084-1093. doi:10.1016/j.jcmg.2018.06.005

60. Chavez-MacGregor M, Niu J, Zhang N, et al. Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer. *J Clin Oncol*. 2015;33(19):2176-2183. doi:10.1200/JCO.2014.58.9465

61. Montazeri K, Unitt C, Foody JM, Harris JR, Partridge AH, Moslehi J. ABCDE steps to prevent heart disease in breast cancer survivors. *Circulation*. 2014;130(18):e157-e159. doi:10.1161/CIRCULATIONAHA.114.008820

62. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. *J Clin Oncol Off J Am Soc Clin Oncol*. 2016;34(6):611-635. doi:10.1200/JCO.2015.64.3809

63. Zoberi K, Tucker J. Primary Care of Breast Cancer Survivors. *Am Fam Physician*. 2019;99(6):370-375.

64. Rothman AJ, Hardin CD. Differential Use of the Availability Heuristic in Social Judgment. *Personal Soc Psychol Bull*. 1997;23(2):123-138. doi:10.1177/0146167297232002

65. Litvak A, Batukbhai B, Russell SD, et al. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. *Cancer*. 2018;124(9):1904-1911. doi:10.1002/cncr.31260

66. Scherr KA, Fagerlin A, Hofer T, et al. Physician recommendations trump patient preferences in prostate cancer treatment decisions. *Med Decis Mak*. 2017;37(1):56-69. doi:10.1177/0272989X16662841

67. Engelhardt EG, Pieterse AH, van der Hout A, et al. Use of implicit persuasion in decision making.
making about adjuvant cancer treatment: A potential barrier to shared decision making.

*Eur J Cancer*. 2016;66:55-66. doi:10.1016/j.ejca.2016.07.011

68. Holmes-Rovner M, Montgomery JS, Rovner DR, et al. Informed Decision Making: Assessment of the Quality of Physician Communication about Prostate Cancer Diagnosis and Treatment. *Med Decis Mak*. 2015;35(8):999-1009. doi:10.1177/0272989X15597226

69. Brust-Renck PG, Royer CE, Reyna VF. Communicating Numerical Risk: Human Factors That Aid Understanding in Health Care. *Rev Hum Factors Ergon*. 2013;8(1):235-276. doi:10.1177/1557234X13492980

70. O'Sullivan ED, Schofield S; Cognitive Bias in Clinical Medicine. *J R Coll Physicians Edinb*. 2018;48(3):225-232. doi:10.4997/JRCPE.2018.306

71. Ellis EM, Elwyn G, Nelson WL, Scalia P, Kobrin SC, Ferrer RA. Interventions to Engage Affective Forecasting in Health-Related Decision Making: A Meta-Analysis. *Ann Behav Med*. 2018;52(2):157-174. doi:10.1093/abm/kax024

72. Hershfield HE, Goldstein DG, Sharpe WF, et al. Increasing Saving Behavior Through Age-Progressed Renderings of the Future Self. *J Mark Res*. 2011;48(SPL):S23-S37. doi:10.1509/jmkr.48.SPL.S23

73. Scholten H, Scheres A, de Water E, Graf U, Granic I, Luijten M. Behavioral trainings and manipulations to reduce delay discounting: A systematic review. *Psychon Bull Rev*. 2019;26(6):1803-1849. doi:10.3758/s13423-019-01629-2

74. Zhang Q, Zhao H, Zheng Y. Effectiveness of mindfulness-based stress reduction (MBSR) on symptom variables and health-related quality of life in breast cancer patients—a systematic review and meta-analysis. *Support Care Cancer*. 2019;27(3):771-781. doi:10.1007/s00520-018-4570-x
75. Cillessen L, Johannsen M, Speckens AEM, Zachariae R. Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta-analysis of randomized controlled trials. *Psychooncology*. 2019;28(12):2257-2269. doi:10.1002/pon.5214

76. Reyna VF, Nelson WL, Han PK, Pignone MP. Decision making and cancer. *Am Psychol.* 2015;70(2):105-118. doi:10.1037/a0036834

77. Zikmund-Fisher BJ, Fagerlin A, Ubel PA. Risky feelings: Why a 6% risk of cancer does not always feel like 6%. *Patient Educ Couns.* 2010;81:S87-S93. doi:10.1016/J.PEC.2010.07.041

78. Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. *Int Rev Psychiatry*. 2014;26(1):102-113. doi:10.3109/09540261.2013.864260

79. Pavone M, Moravek MB, Lawson AK, et al. Fertility preservation (FP) in breast cancer patients does not delay time to cancer treatment. *Fertil Steril*. 2017;108(3):e184. doi:10.1016/j.fertnstert.2017.07.546

80. Covelli A, Facey M, Kennedy E, et al. Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer. *JAMA Netw open*. 2019;2(11):e1914511. doi:10.1001/jamanetworkopen.2019.14511